Usrc Tarrant Dialysis Center Mansfield is a medicare approved dialysis facility center in Mansfield, Texas and it has 23 dialysis stations. It is located in Tarrant county at 1800 Hwy 157 N., Mansfield, TX, 76063. You can reach out to the office of Usrc Tarrant Dialysis Center Mansfield at (682) 518-0126. This dialysis clinic is managed and/or owned by Tarrant Dialysis Centers. Usrc Tarrant Dialysis Center Mansfield has the following ownership type - Profit. It was first certified by medicare in October, 2004. The medicare id for this facility is 452896 and it accepts patients under medicare ESRD program.
| Name | Usrc Tarrant Dialysis Center Mansfield |
|---|---|
| Location | 1800 Hwy 157 N., Mansfield, Texas |
| No. of Dialysis Stations | 23 |
| Medicare ID | 452896 |
| Managed By | Tarrant Dialysis Centers |
| Ownership Type | Profit |
| Late Shifts | No |
| 1800 Hwy 157 N., Mansfield, Texas, 76063 | |
| (682) 518-0126 | |
News Archive
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.
Pivotal response treatment involving parents works better than other existing therapies at motivating children with autism and significant speech delays to talk, according to the results of a large study by researchers at the Stanford University School of Medicine.
According to new research, though male circumcision protects men from HIV, it does not protect them against other common sexually transmitted infections such as chlamydia, genital warts and genital herpes.
GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has been granted a second U.S. patent for its core platform technology, the Sentinel Principle(R). U.S. Patent # 7,662,558, entitled "Method of profiling gene expression in a human subject."
PurGenesis Technologies, Inc. today announced the successful completion of the development of a unique line of anti-aging cosmeceutical products. The product line consists of three unique, anti-aging formulations: Day Cream, Night Cream and Eye Cream.
› Verified 2 days ago
| NPI Number | 1336195841 |
| Organization Name | Usrc Tarrant Dialysis Mansfield |
| Doing Business As | Usrc Tarrant Lp |
| Address | 1800 Highway 157 N Ste 101 Mansfield, Texas, 76063 |
| Phone Number | (682) 518-0126 |
News Archive
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.
Pivotal response treatment involving parents works better than other existing therapies at motivating children with autism and significant speech delays to talk, according to the results of a large study by researchers at the Stanford University School of Medicine.
According to new research, though male circumcision protects men from HIV, it does not protect them against other common sexually transmitted infections such as chlamydia, genital warts and genital herpes.
GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has been granted a second U.S. patent for its core platform technology, the Sentinel Principle(R). U.S. Patent # 7,662,558, entitled "Method of profiling gene expression in a human subject."
PurGenesis Technologies, Inc. today announced the successful completion of the development of a unique line of anti-aging cosmeceutical products. The product line consists of three unique, anti-aging formulations: Day Cream, Night Cream and Eye Cream.
› Verified 2 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 60% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 13% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 27% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 45% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 30% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 25% | 14% |
News Archive
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.
Pivotal response treatment involving parents works better than other existing therapies at motivating children with autism and significant speech delays to talk, according to the results of a large study by researchers at the Stanford University School of Medicine.
According to new research, though male circumcision protects men from HIV, it does not protect them against other common sexually transmitted infections such as chlamydia, genital warts and genital herpes.
GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has been granted a second U.S. patent for its core platform technology, the Sentinel Principle(R). U.S. Patent # 7,662,558, entitled "Method of profiling gene expression in a human subject."
PurGenesis Technologies, Inc. today announced the successful completion of the development of a unique line of anti-aging cosmeceutical products. The product line consists of three unique, anti-aging formulations: Day Cream, Night Cream and Eye Cream.
› Verified 2 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 57% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 23% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 20% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 47% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 40% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 13% | 12% |
News Archive
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.
Pivotal response treatment involving parents works better than other existing therapies at motivating children with autism and significant speech delays to talk, according to the results of a large study by researchers at the Stanford University School of Medicine.
According to new research, though male circumcision protects men from HIV, it does not protect them against other common sexually transmitted infections such as chlamydia, genital warts and genital herpes.
GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has been granted a second U.S. patent for its core platform technology, the Sentinel Principle(R). U.S. Patent # 7,662,558, entitled "Method of profiling gene expression in a human subject."
PurGenesis Technologies, Inc. today announced the successful completion of the development of a unique line of anti-aging cosmeceutical products. The product line consists of three unique, anti-aging formulations: Day Cream, Night Cream and Eye Cream.
› Verified 2 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 84% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 16% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 51% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 28% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 21% | 12% |
News Archive
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.
Pivotal response treatment involving parents works better than other existing therapies at motivating children with autism and significant speech delays to talk, according to the results of a large study by researchers at the Stanford University School of Medicine.
According to new research, though male circumcision protects men from HIV, it does not protect them against other common sexually transmitted infections such as chlamydia, genital warts and genital herpes.
GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has been granted a second U.S. patent for its core platform technology, the Sentinel Principle(R). U.S. Patent # 7,662,558, entitled "Method of profiling gene expression in a human subject."
PurGenesis Technologies, Inc. today announced the successful completion of the development of a unique line of anti-aging cosmeceutical products. The product line consists of three unique, anti-aging formulations: Day Cream, Night Cream and Eye Cream.
› Verified 2 days ago
| Dialysis patients with Hemoglobin data | 49 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 6 |
News Archive
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.
Pivotal response treatment involving parents works better than other existing therapies at motivating children with autism and significant speech delays to talk, according to the results of a large study by researchers at the Stanford University School of Medicine.
According to new research, though male circumcision protects men from HIV, it does not protect them against other common sexually transmitted infections such as chlamydia, genital warts and genital herpes.
GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has been granted a second U.S. patent for its core platform technology, the Sentinel Principle(R). U.S. Patent # 7,662,558, entitled "Method of profiling gene expression in a human subject."
PurGenesis Technologies, Inc. today announced the successful completion of the development of a unique line of anti-aging cosmeceutical products. The product line consists of three unique, anti-aging formulations: Day Cream, Night Cream and Eye Cream.
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 124 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 1128 |
| Percentage of adult patients getting regular hemodialysis at the center | 97 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.
Pivotal response treatment involving parents works better than other existing therapies at motivating children with autism and significant speech delays to talk, according to the results of a large study by researchers at the Stanford University School of Medicine.
According to new research, though male circumcision protects men from HIV, it does not protect them against other common sexually transmitted infections such as chlamydia, genital warts and genital herpes.
GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has been granted a second U.S. patent for its core platform technology, the Sentinel Principle(R). U.S. Patent # 7,662,558, entitled "Method of profiling gene expression in a human subject."
PurGenesis Technologies, Inc. today announced the successful completion of the development of a unique line of anti-aging cosmeceutical products. The product line consists of three unique, anti-aging formulations: Day Cream, Night Cream and Eye Cream.
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Usrc Tarrant Dialysis Center Mansfield with elevated calcium levels.
| Patients with hypercalcemia | 126 |
| Hypercalcemia patient months | 1141 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 135 |
| Patients with Serumphosphor less than 3.5 mg/dL | 10 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 24 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 34 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 14 |
| Patients with Serumphosphor greater than 7 mg/dL | 18 |
News Archive
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.
Pivotal response treatment involving parents works better than other existing therapies at motivating children with autism and significant speech delays to talk, according to the results of a large study by researchers at the Stanford University School of Medicine.
According to new research, though male circumcision protects men from HIV, it does not protect them against other common sexually transmitted infections such as chlamydia, genital warts and genital herpes.
GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has been granted a second U.S. patent for its core platform technology, the Sentinel Principle(R). U.S. Patent # 7,662,558, entitled "Method of profiling gene expression in a human subject."
PurGenesis Technologies, Inc. today announced the successful completion of the development of a unique line of anti-aging cosmeceutical products. The product line consists of three unique, anti-aging formulations: Day Cream, Night Cream and Eye Cream.
› Verified 2 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 89 |
| Patient months included in arterial venous fistula and catheter summaries | 685 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 58 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 25 |
News Archive
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.
Pivotal response treatment involving parents works better than other existing therapies at motivating children with autism and significant speech delays to talk, according to the results of a large study by researchers at the Stanford University School of Medicine.
According to new research, though male circumcision protects men from HIV, it does not protect them against other common sexually transmitted infections such as chlamydia, genital warts and genital herpes.
GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has been granted a second U.S. patent for its core platform technology, the Sentinel Principle(R). U.S. Patent # 7,662,558, entitled "Method of profiling gene expression in a human subject."
PurGenesis Technologies, Inc. today announced the successful completion of the development of a unique line of anti-aging cosmeceutical products. The product line consists of three unique, anti-aging formulations: Day Cream, Night Cream and Eye Cream.
› Verified 2 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 118 |
| Hospitalization Rate in facility | 185.7 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 305.9 |
| Hospitalization Rate: Lower Confidence Limit | 121.5 |
News Archive
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.
Pivotal response treatment involving parents works better than other existing therapies at motivating children with autism and significant speech delays to talk, according to the results of a large study by researchers at the Stanford University School of Medicine.
According to new research, though male circumcision protects men from HIV, it does not protect them against other common sexually transmitted infections such as chlamydia, genital warts and genital herpes.
GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has been granted a second U.S. patent for its core platform technology, the Sentinel Principle(R). U.S. Patent # 7,662,558, entitled "Method of profiling gene expression in a human subject."
PurGenesis Technologies, Inc. today announced the successful completion of the development of a unique line of anti-aging cosmeceutical products. The product line consists of three unique, anti-aging formulations: Day Cream, Night Cream and Eye Cream.
› Verified 2 days ago
The rate of readmission show you whether patients who were being treated regularly at Usrc Tarrant Dialysis Center Mansfield were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 22.2 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 30.8 |
| Readmission Rate: Lower Confidence Limit | 15.1 |
News Archive
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.
Pivotal response treatment involving parents works better than other existing therapies at motivating children with autism and significant speech delays to talk, according to the results of a large study by researchers at the Stanford University School of Medicine.
According to new research, though male circumcision protects men from HIV, it does not protect them against other common sexually transmitted infections such as chlamydia, genital warts and genital herpes.
GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has been granted a second U.S. patent for its core platform technology, the Sentinel Principle(R). U.S. Patent # 7,662,558, entitled "Method of profiling gene expression in a human subject."
PurGenesis Technologies, Inc. today announced the successful completion of the development of a unique line of anti-aging cosmeceutical products. The product line consists of three unique, anti-aging formulations: Day Cream, Night Cream and Eye Cream.
› Verified 2 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Usrc Tarrant Dialysis Center Mansfield get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .78 (As Expected) |
| SIR: Upper Confidence Limit | 1.43 |
| SIR: Lower Confidence Limit | .38 |
News Archive
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.
Pivotal response treatment involving parents works better than other existing therapies at motivating children with autism and significant speech delays to talk, according to the results of a large study by researchers at the Stanford University School of Medicine.
According to new research, though male circumcision protects men from HIV, it does not protect them against other common sexually transmitted infections such as chlamydia, genital warts and genital herpes.
GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has been granted a second U.S. patent for its core platform technology, the Sentinel Principle(R). U.S. Patent # 7,662,558, entitled "Method of profiling gene expression in a human subject."
PurGenesis Technologies, Inc. today announced the successful completion of the development of a unique line of anti-aging cosmeceutical products. The product line consists of three unique, anti-aging formulations: Day Cream, Night Cream and Eye Cream.
› Verified 2 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Usrc Tarrant Dialysis Center Mansfield's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 103 |
| Transfusion Rate in facility | 56.8 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 106 |
| Transfusion Rate: Lower Confidence Limit | 32.8 |
News Archive
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.
Pivotal response treatment involving parents works better than other existing therapies at motivating children with autism and significant speech delays to talk, according to the results of a large study by researchers at the Stanford University School of Medicine.
According to new research, though male circumcision protects men from HIV, it does not protect them against other common sexually transmitted infections such as chlamydia, genital warts and genital herpes.
GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has been granted a second U.S. patent for its core platform technology, the Sentinel Principle(R). U.S. Patent # 7,662,558, entitled "Method of profiling gene expression in a human subject."
PurGenesis Technologies, Inc. today announced the successful completion of the development of a unique line of anti-aging cosmeceutical products. The product line consists of three unique, anti-aging formulations: Day Cream, Night Cream and Eye Cream.
› Verified 2 days ago
The rate of mortality show you whether patients who were being treated regularly at Usrc Tarrant Dialysis Center Mansfield lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 596 |
| Mortality Rate in facility | 19.9 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 24.9 |
| Mortality Rate: Lower Confidence Limit | 15.6 |
News Archive
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.
Pivotal response treatment involving parents works better than other existing therapies at motivating children with autism and significant speech delays to talk, according to the results of a large study by researchers at the Stanford University School of Medicine.
According to new research, though male circumcision protects men from HIV, it does not protect them against other common sexually transmitted infections such as chlamydia, genital warts and genital herpes.
GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has been granted a second U.S. patent for its core platform technology, the Sentinel Principle(R). U.S. Patent # 7,662,558, entitled "Method of profiling gene expression in a human subject."
PurGenesis Technologies, Inc. today announced the successful completion of the development of a unique line of anti-aging cosmeceutical products. The product line consists of three unique, anti-aging formulations: Day Cream, Night Cream and Eye Cream.
› Verified 2 days ago
Usrc Tarrant Dialysis Center Mansfield Location: 1800 Hwy 157 N., Mansfield, Texas, 76063 Phone: (682) 518-0126 |
Mansfield Dialysis Center Location: 352 Matlock Drive Suite 120, Mansfield, Texas, 76063 Phone: (817) 453-8167 |
Liberty Dialysis - Mansfield Location: 2651 E Broad Street, Mansfield, Texas, 76063 Phone: (817) 225-4433 |
News Archive
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.
Pivotal response treatment involving parents works better than other existing therapies at motivating children with autism and significant speech delays to talk, according to the results of a large study by researchers at the Stanford University School of Medicine.
According to new research, though male circumcision protects men from HIV, it does not protect them against other common sexually transmitted infections such as chlamydia, genital warts and genital herpes.
GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has been granted a second U.S. patent for its core platform technology, the Sentinel Principle(R). U.S. Patent # 7,662,558, entitled "Method of profiling gene expression in a human subject."
PurGenesis Technologies, Inc. today announced the successful completion of the development of a unique line of anti-aging cosmeceutical products. The product line consists of three unique, anti-aging formulations: Day Cream, Night Cream and Eye Cream.
› Verified 2 days ago